Compare CFLT & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CFLT | KYMR |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 6.6B |
| IPO Year | N/A | N/A |
| Metric | CFLT | KYMR |
|---|---|---|
| Price | $30.66 | $84.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 29 | 24 |
| Target Price | $29.13 | ★ $105.96 |
| AVG Volume (30 Days) | ★ 18.8M | 776.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.28 | $18.36 |
| Revenue Next Year | $16.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.64 | $19.45 |
| 52 Week High | $35.76 | $103.00 |
| Indicator | CFLT | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 69.01 | 65.24 |
| Support Level | $30.49 | $76.52 |
| Resistance Level | $30.60 | $86.18 |
| Average True Range (ATR) | 0.12 | 3.95 |
| MACD | -0.08 | 1.13 |
| Stochastic Oscillator | 98.72 | 92.10 |
Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.